ReviewDrug delivery and translational research2019
Delivery of therapeutic miRNA using polymer-based formulation.
Review in Drug delivery and translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 69 citations in OpenAlex.
- MicroRNAs in Breast Cancer: Biological Functions and Technologies for Experimental and Therapeutic Applications.Cancers · 2026Review
- MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.British journal of haematology · 2026Review
- The harmonies played by miR-302/367 cluster in pluripotency, reprogramming, and rejuvenation.Stem cells translational medicine · 2026Review
- MicroRNA chemical modifications in post-transcriptional gene silencing and human diseases.Molecular therapy. Nucleic acids · 2025Review
- MiRNA-based drugs: challenges and delivery strategies.Applied microbiology and biotechnology · 2025Review
- MicroRNA-Based Delivery Systems for Chronic Neuropathic Pain Treatment in Dorsal Root Ganglion.Pharmaceutics · 2025Review
- Exploring the Therapeutic Potential: Antisense RNA Delivery Via Bacteriophage Platform.Iranian journal of biotechnology · 2025Review
- Article
- Enhancing HepG2 cell apoptosis with a combined nanoparticle delivery of miR-128-3p agomir and Oroxin B: A novel drug delivery approach based on PI3K-AKT and VEGF pathway crosstalk.Asian journal of pharmaceutical sciences · 2025Article
- MicroRNA-targeted nanoparticle delivery systems for cancer therapy: current status and future prospects.Nanomedicine (London, England) · 2025Review
- Review
- Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment.International journal of nanomedicine · 2025Review
- MicroRNA-26a in respiratory diseases: mechanisms and therapeutic potential.Molecular biology reports · 2024Review
- MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage.Biomarker research · 2024Review
- miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.Cells · 2023Review
- Review
- A short review on the applicability and use of cubosomes as nanocarriers.Biophysical reviews · 2023Review
- Optimization and characterization of miRNA-129-5p-encapsulated poly (lactic-Nanoscale advances · 2023Article
- MicroRNAs-Based Theranostics against Anesthetic-Induced Neurotoxicity.Pharmaceutics · 2023Review
- Effects of Dendrimer-microRNA Nanoformulations against Glioblastoma Stem Cells.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are short non-coding RNAs that play important roles in many cellular processes such as development, proliferation, differentiation, and apoptosis. For this reason, miRNAs have been proposed and investigated as biomarkers and therapeutics for various diseases such as cancer, diabetes, and cardiovascular disease. However, delivery of miRNAs and their antagomirs to target sites remains challenging because of poor cellular uptake and degradation by nucleases. Various delivery systems have been investigated for enhanced delivery of miRNAs to cells, organs, and tissues of interest, thereby enabling evaluation of their biological functions and clinical trials. In particular, non-viral, polymer-based carriers have shown advantages such as versatility of structural modifications and protection of unstable miRNA. Herein, we review properties and applications of poly (lactic-co-glycolic acid), chitosan, polyethyleneimine, and polyamidoamine dendrimers as carriers for effective delivery systems of miRNA mimic or anti-miRNAs that directly target essential miRNAs and/or their target genes. A number of miRNAs in clinical trials appear to use chemically modified miRNAs without any particular delivery system except one study with liposomal miRNA. With more accumulation of positive research results on polymeric delivery of miRNA in vitro and in vivo, we expect that polymeric delivery system will accelerate advancement of miRNA therapeutics to clinical study in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.